Currently, our core product Lockdown LSSS™, is a double braided augmentation device, designed to provide fixation during the healing process following an acromioclavicular separation due to coracoclavicular ligament disruption.
With over 2,000 implantations globally every year, the Lockdown LSSS™ device offers excellent clinical results and patient satisfaction outcomes. A simple, reproducible surgical procedure requires no holes in the coracoid and a fast rehabilitation process.
The patient’s arm is supported by a sling at 2 weeks post operatively, and the most exacting activities (including contact sports) can be resumed after 12 weeks. The Lockdown LSSS™ device is CE marked and gained FDA approval for use in February 2011.
Lockdown Medical Ltd currently distribute products to Australia, Belgium, Germany, Greece, Ireland, Israel, Italy, Netherlands, Malaysia, Scandinavia, South Africa, UAE and the USA. We are currently seeking other distribution partners around the world.
Our team is made up of product and design engineers, customer support staff and a dedicated senior management team.
We are registered with BSI and hold Certificate no. MD 534510 and operate a Quality Management System which complies with the requirements of ISO 13485:2016.
We are registered with the FDA in the USA, Registration no. 8020712 FEI No. 3008237817.
Our products are CE-marked Certificate No. CE 00403.
Our VAT number is 933 8359 95.
Website designed and produced by marketing agency Creative Tweed.